News for Omeros Corporation (OMER)

Key Highlights: Omeros Corporation announces a significant stock transaction with Polar Asset Management Partners. Analysts project a substantial upside

Omeros Corporation (Nasdaq: OMER) (”œOmeros” or the ”œCompany”) announced that on July 24, 2025 it entered into a securities purchase agreement with Pola

Omeros Corporation (OMER) announces a $22 million registered direct offering. Shares priced at $4.10 each, a 14% premium over the previous closing price

Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) f

Omeros Corporation (OMER) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its drug narsoplimab, aimed

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Omeros faces critical liquidity challenges, with limited cash runway and rising dilution risks. Its cash runway is dangerously short. See more on OMER here.

Operator: Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.

Weekly Market Recap Stocks had a winning week with the S&P 500 and Dow Jones Industrial Average turning positive for the year, up by 1.3% and 0.3% respecti

May 15, 2025 / 08:30PM GMTOperator Good afternoon and welcome to today's earnings call for Omeros Corporation. (Operator Instructions) Please be advised that th

Summary: Omeros Corporation (OMER) reduces 2026 debt by $10 million, extending maturity to 2029. Focuses on capital for possible FDA approval and market

Discover key insights from Omeros Corporation's Q1 2025 earnings call. Learn about narsoplimab launch readiness, debt reduction, and FDA approval timelines.

Omeros Corporation (NASDAQ:OMER) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ETCompany ParticipantsJennifer Williams - Investor and Media...

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, w

Omeros Corporation (OMER) has achieved a significant milestone as the FDA has accepted its Biologics License Application (BLA) for narsoplimab, a treatment aime

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15,

Omeros Corporation (OMER) to release Q1 2025 financial results on May 15, 2025. Conference call and webcast scheduled at 4:30 p.m. Eastern Time for detailed

Omeros Corporation (OMER) announces a strategic debt restructuring involving convertible notes. Analysts predict a significant price increase for OMER,

Omeros Corporation (OMER) has resumed trading after a temporary halt earlier. Investors are keenly watching developments as the company re-enters the market. Th